Federal business grant programs (SBIR – STTR) represent over $2.5 billion in available funding, with over $1 billion of that focused on the life-sciences. The Department or Defense’s “Congressionally Directed Medical Research Program” (CDMRP) program provides and additional $1 billion plus specifically for medical research. Such funding can be a significant source of revenue – a life-science company that wins Phase I – Phase IIb SBIR/STTR funding from the NIH for example can secure over $4.7M in non-dilutive capital and CDMRP grants can be even larger.
For early stage companies, the G2B program is closely coordinated with Fundamentals to help G2B candidates develop sound business models and teams. In its first year of operation, the G2B program has supported early stage companies that have won “fundable” scores on grant applications totaling $13,375,000.
The program provides entrepreneurs with the support necessary to craft competitive business models and grant applications. The program runs three annual cycles using an “Incentive Driven Calendar” – companies win support resources by achieving specific business development milestones by specific dates in each cycle. (All support is free of charge.)
G2B support includes:
We aim to significantly increase Missouri’s life-science business grant funding so that Missouri’s rank equals our population rank by 2019 and our academic grant rank by 2021.
Do you think you have a great business idea, but need funding? BioGenerator is hosting a free two-day SBIR/STTR training workshop October 17 – 18 to help companies navigate the application process.
Developing SBIR/STTR proposals is a complex process with a steep learning curve, but the impact of receiving $millions in non-dilutive funding is worth the effort! This 2-day workshop is timed to coincide with the January 5, 2018, National Institutes of Health’s (NIH) deadline and will provide detailed instruction on developing a competitive proposal for the NIH SBIR/STTR program.
"The input from the mock panel was extremely valuable. The format also allowed us to advance our planning in a way that was beneficial. This is a useful aid for start-ups and we will certainly use it again."
– David Curiel, MD, PhD
Professor, Washington University
Co-Founder, Unleash Immuno Oncolytics
Founder, Precision Virologics